Novartis AveXis President Lennon On Rebuilding Trust With FDA, Zolgensma Trial Hold, And More
Executive Summary
AveXis President David Lennon talked to Pink Sheet about quality enhancement at the gene therapy unit, a clinical trial hold for Zolgensma in Type 2 SMA, and expansion in gene therapy.